SEC Form 4 · accession 0001209191-15-007127
ALDER BIOPHARMACEUTICALS INC · ALDR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John A Latham
Officer — Chief Scientific Officer
Period of report
Jan 26, 2015
Accepted (ET)
Jan 28, 2015 · 5:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001423824
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 26, 2015 | M | 7,900 | $0.385 | A | 216,888 | D | |
| Common StockF3,F4 | Jan 26, 2015 | S | 7,900 | $27.9757 | D | 208,988 | D | |
| Common StockF1 | Jan 27, 2015 | M | 7,145 | $0.385 | A | 216,133 | D | |
| Common StockF3,F5 | Jan 27, 2015 | S | 7,145 | $28.7303 | D | 208,988 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $28.23 | Jan 26, 2015 | A | 60,000 | A | — | Jan 25, 2025 | Common Stock | 60,000 | 60,000 | D |
| Stock Option (Right to Buy)F7 | $0.385 | Jan 26, 2015 | M | 7,900 | D | — | Sep 14, 2016 | Common Stock | 7,900 | 92,100 | D |
| Stock Option (Right to Buy)F7 | $0.385 | Jan 27, 2015 | M | 7,145 | D | — | Sep 14, 2016 | Common Stock | 7,145 | 84,955 | D |
Explanation of responses
- F1The exercise of options reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2014.
- F2Includes 504 shares acquired under the Issuer's 2014 Employee Stock Purchase Plan on November 28, 2014.
- F3The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2014.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.97 to $28.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $30.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 5 to this Form 4.
- F6The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of the vesting commencement date and 1/48th of the total number of shares each monthly anniversary of the vesting commencement date thereafter, for so long as the recipient of the option provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.
- F7The option was fully vested.